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Edited by Sandro SonninoAbstract Sphingosine kinase type 1 (SphK1) and its product
sphingosine-1-phosphate have been shown to promote cell growth
and inhibit apoptosis of tumor cells. In an eﬀort to further
understand the regulation of SphK1, we used a yeast two-hybrid
screen to ﬁnd SphK1-interacting proteins. One of these was
identiﬁed as aminoacylase 1 (Acy1), a metalloenzyme that
removes amide-linked acyl groups from amino acids and may
play a role in regulating responses to oxidative stress. Both the
C-terminal fragment found in the two-hybrid screen and full-
length Acy1 co-immunoprecipitate with SphK1. Though both C-
terminal and full-length proteins slightly reduce SphK1 activity
measured in vitro, the C-terminal fragment inhibits while full-
length Acy1 potentiates the eﬀects of SphK1 on proliferation and
apoptosis. Interestingly, Acy1 induces redistribution of SphK1 as
observed by immunocytochemistry and subcellular fractionation.
Collectively, our data suggest that Acy1 physically interacts with
SphK1 and may inﬂuence its physiological functions.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Sphingolipids are ubiquitous constituents of eukaryotic
membranes whose backbones consist of an acylated sphingoid
base, ceramide. Ceramide and its further metabolites, sphin-
gosine and sphingosine-1-phosphate (S1P), are now recognized
as potent signaling molecules. In many cell types, increased
ceramide and sphingosine levels lead to cell growth arrest and
apoptosis [1,2]. Conversely, S1P promotes cell growth and
inhibits apoptosis [3–5]. Cells contain enzymes that can rapidly
interconvert ceramide, sphingosine, and S1P. Thus, conversion
of ceramide and sphingosine to S1P simultaneously removes
pro-apoptotic signals and creates a survival signal, and vice
versa [6–9]. While many early studies suggested a role for S1P
as an intracellular second messenger, it was later convincingly
demonstrated that S1P is also a ligand for a family of G
protein-coupled receptors [5,10]. Complicating matters, there
is growing evidence that agonist-induced sphingosine kinase* Corresponding author. Fax: +1-804-828-8999.
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doi:10.1016/j.febslet.2004.04.093(SphK) activation leads to S1P secretion [11,12] and autocrine
and/or paracrine signaling through cell surface S1P receptors
[13–15].
Recently, progress has been made in elucidating the molec-
ular mechanisms of activation of SphK type 1 (SphK1). It has
been shown that PKC can phosphorylate SphK1, both acti-
vating SphK1 and inducing its translocation to the plasma
membrane [12]. More recently, it has been demonstrated that
activation and translocation of SphK1 from the cytosol to the
plasma membrane results directly from phosphorylation at
Ser225 by ERK1/2 [16]. SphK1 interacts with TRAF2, an
interaction that is required for suppression of apoptosis by
TNF-a [17]. Several other SphK1-interacting proteins have
also recently been identiﬁed, including PECAM-1 [18],
RPK118 [19], and AKAP-related protein SKIP1 [20], which
are involved in the translocation of SphK1 to the plasma
membrane, endosomes, and signaling complexes, respectively.
In a yeast two-hybrid search for additional SphK1-inter-
acting proteins, we cloned aminoacylase 1 (Acy1) and showed
that it interacted with SphK1 and aﬀected its activity and
biological functions.2. Materials and methods
2.1. Cell culture and transfection
Cos7, HEK 293, and NIH 3T3 cells were obtained from ATCC.
Cells were cultured in DMEM supplemented with 10% fetal bovine
(Cos7, HEK) or 10% calf serum (NIH) and maintained at 37 C in a
humidiﬁed environment in 5% CO2. All culture reagents were from
BioFluids. HEK 293 cells, plated on poly-D-lysine, and NIH 3T3 cells
were transfected using Lipofectamine Plus and Cos7 cells with Lipo-
fectamine 2000 (Invitrogen).
2.2. Two-hybrid screen and cloning
The two-hybrid screen was carried out using the MatchMaker II Kit
from Clontech as described [20] with mouse SphK1a as bait against a
mouse kidney cDNA library (Clontech). A clone of the C-terminal
portion of Acy1 (CT-Acy1) was obtained from this screen that passed
all tests as a valid two-hybrid interactor. The CT-Acy1 was removed
from the library vector using EcoRI and BamH1 and cloned into
pcDNA3-HA (N-terminal tag). Full-length Acy1 was cloned by PCR
from a mouse kidney library using the V5-His-Topo Cloning Kit
(Invitrogen).
2.3. Sphingosine kinase assay
SphK1 activity was measured essentially as described [21] with
sphingosine solubilized in Triton X-100 (0.25% ﬁnal concentration).
2.4. GST pulldown and immunoprecipitation
The CT-Acy1 was transcribed and translated in vitro with the TnT
Kit (Promega) in the presence of [3H]leucine. The translation mix wasation of European Biochemical Societies.
Fig. 1. SphKl physically interacts with Acy1. (A) Schematic repre-
sentation of full-length Acy1 (top) and CT-Acy1, the C-terminal
fragment pulled out of the two-hybrid screen. Hatched box indicates
conserved regions (aa 78–148) amongst Acy1 family members across
kingdoms, H indicates the conserved catalytic histidine, and shaded
boxes indicate putative dimerization domains. (B) [3H]-labeled CT-
Acy1 prepared by in vitro transcription–translation was incubated
with either GST or GST-SphKl. Glutathione–Sepharose beads were
then added. After overnight incubation at 4 C, beads were washed
and bound proteins resolved by SDS–PAGE and autoradiographed.
GST-SphKl precipitated 22 kDa radiolabeled CT-Acy1. The data are
representatives of two independent experiments. (C) HEK 293 cells
were co-transfected with V5-Acy1 and either vector or myc-SphKl.
Cells were then lysed and immunoprecipitated with anti-myc anti-
bodies followed by protein A/G–Sepharose. The pellets were resolved
by SDS–PAGE and immunoblotted with anti-V5. Lysate indicates 1/
100 of the total protein immunoprecipitated. Similar results were ob-
tained in two additional experiments.
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ﬁnity-puriﬁed using glutathione–Sepharose beads (Pierce), and washed
three times with SphK assay buﬀer containing 1% Triton X-100. The
pellet was resuspended in sample buﬀer and proteins resolved by SDS–
PAGE. Gels were dried and exposed to ﬁlm. For immunoprecipitation,
HEK 293 transfectants were lysed and 800 lg lysate incubated with
anti-myc antibodies for 24 h at 4 C. Anti-myc immunocomplexes were
precipitated with protein A/G Sepharose (Santa Cruz) and washed
three times with SphK assay buﬀer containing 1% Triton X-100. The
pellets were resuspended in sample buﬀer, proteins resolved by SDS–
PAGE, and immunoblotted with anti-HA (CT-Acy1) or anti-V5
(Acy1).
2.5. Apoptosis and MTT assays
48 h after transfection, NIH 3T3 cells were serum-starved for 24 h to
induce apoptosis. Cells were ﬁxed with 4% paraformaldehyde in 4%
sucrose–PBS and stained with 8 lg/ml Hoechst. Apoptotic nuclei were
scored essentially as described [20]. Cell viability was assessed by the
MTT dye reduction assay (Roche).
2.6. Fractionation and immunoﬂuorescence
Cells were plated on 10-cm dishes. 48 h after transfection, cells were
washed and harvested in SphK buﬀer. Cells were lysed by freeze–thaw
and then centrifuged at 100 000 g. Supernatants were removed (cy-
tosol) and pellets washed with SphK buﬀer. Pellets were then resus-
pended in SphK buﬀer containing 1% Triton X-100 and solubilized on
ice for 1 h. Solubilized pellets were centrifuged at 100 000 g for 30
min and supernatants (Triton soluble, TS) and pellets (Triton insolu-
ble, TI) were then separated. TI pellets were resuspended in SphK
buﬀer plus 1% Triton X-100. Western blotting was used to determine
protein expression with either anti-myc (9E10; Santa Cruz), anti-HA
(3F10; Roche), or anti-V5 (monoclonal from Invitrogen or rabbit
polyclonal from Sigma–Aldrich) as primary antibodies followed by
HRP-conjugated secondary antibodies (1:10 000, Jackson Immuno-
Research Laboratories). Immunocomplexes were visualized by en-
hanced chemiluminescence (Pierce) as described previously [22].
For immunoﬂuorescence, cells were plated on #1 coverslips, trans-
fected, and after 48 h, ﬁxed in 3.7% formalin and stained essentially as
described [20]. Brieﬂy, after washing with PBS containing 10 mM
glycine, cells were permeabilized for 3 min with 0.5% Triton X-100 in
PBS–glycine, washed again, and incubated for 20 min at room tem-
perature with mouse monoclonal anti-myc (2 lg/ml) for detection of
SphK1 and rabbit anti-V5 (4 lg/ml) for Acy1. After washing, cells
were incubated for 20 min with Texas Red-conjugated anti-mouse and
FITC-conjugated anti-rabbit secondary antibodies (1 lg/ml each;
Jackson ImmunoResearch). Coverslips were then mounted with glyc-
erol containing 10 mM n-propyl gallate and images collected with a
Nikon TE-200 ﬂuorescence microscope.3. Results and discussion
3.1. Acy1 is a SphK1-interacting protein
To search for proteins that interact with SphK1 and regulate
its activity or translocation to the plasma membrane, a two-
hybrid screen was carried out using mouse SphK1 fused to the
DNA binding domain of GAL4 as bait. The prey consisted of
a mouse kidney cDNA library (Clontech) fused to the tran-
scriptional activation domain of GAL4. Interaction between
SphK1 and a library protein brings together the two domains
necessary for transcription of reporter genes. The Match-
Maker II system mitigates against false positives by having
three diﬀerent promoter–reporter gene constructs, with diﬀer-
ing aﬃnities for the GAL4 DNA-binding domain. This re-
duces the chances that the prey construct activates on its own
by binding regions around the GAL4 DNA binding site or to
speciﬁc TATA boxes and allows for control of stringency.
Using the most stringent interaction test, a clone of the CT-
Acy1, starting at amino acid 232 of the full-length protein
(Fig. 1A), was obtained. Acy1 has been characterized as acytosolic homodimeric metalloenzyme of amino acid salvage
[23], catalyzing the hydrolysis of amide-linked acyl chains of
amino acids. It is the major acylase that degrades N-acetyl-
cysteine [24], and thus may play a role in the regulation of
cellular redox status. Acy1 is abundant in the kidney and brain
[24], two tissues with high SphK1 levels [25]. CT-Acy1 is not
expected to be active because it lacks conserved residues nec-
essary for binding essential Zn ions and it has a truncated
catalytic domain [26] (Fig. 1A).
To examine whether CT-Acy1 interacts physically with
SphK1, [3H]-labeled CT-Acy1 was synthesized by in vitro
transcription–translation, incubated with either GST or
GST-SphK1 [20] and binding was determined using glutathi-
one–Sepharose beads. Sepharose-bound proteins were then
resolved by SDS–PAGE and 3H-labeled proteins visualized by
autoradiography. CT-Acy1 speciﬁcally interacted with GST-
SphK1, but not with GST alone (Fig. 1B).3.2. Acy1 interacts with SphK1 in vivo
To determine if Acy1 interacts with SphK1 when expressed
in mammalian cells, HEK 293 cells were co-transfected with
Acy1 and SphK1. Lysates were immunoprecipitated with an-
tibodies to SphK1 and the blots probed with antibodies to
either CT-Acy1 or Acy1. Both CT-Acy1 (data not shown) and
full-length Acy1 co-immunoprecipitated with SphK1
Fig. 2. Eﬀect of Acy1 on activity and function of SphK1. (A) SphK1 activity. HEK 293 cells were co-transfected with myc-SphK1 and vector, CT-
Acy1, or Acy1. After 48 h, cells were lysed and SphK1 activity measured. Inset shows equal expression of SphK1 as determined by Western blotting
with anti-myc. The data are representatives of three independent experiments. (B) Cytoprotective eﬀects of SphK1. NIH 3T3 cells stably transfected
with vector (open bars) or SphK1 (ﬁlled bars) were transiently transfected with either Acy1, CT-Acy1, or empty vector, together with GFP at a 5:1
ratio, and then serum-starved. After 24 h, cells were ﬁxed and stained with Hoechst. Total GFP-expressing cells and GFP-expressing cells displaying
fragmented nuclei indicative of apoptosis were enumerated. Data are meansS.D. Three independent wells were counted for each treatment, with a
minimum of 100 cells scored per well. Data are representatives of two independent experiments. (C) Proliferative eﬀects of SphK1. Cells transfected
with the indicated constructs were plated at equal density and allowed to grow for 24 h. Cell proliferation was determined by MTT dye reduction.
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and the original two-hybrid data, indicates that SphK1 and
Acy1 physically interact in vivo.
3.3. Eﬀects of Acy1 on SphK1 activity and biological functions
We next examined whether the physical interaction with
Acy1 aﬀects SphK1 biological functions. Co-transfection of
SphK1 with either CT-Acy1 or Acy1 slightly decreased SphK1
activity measured in vitro, without aﬀecting its expression level
(Fig. 2A). The best characterized biological responses of
SphK1 are suppression of apoptosis and stimulation of cell
proliferation and entry into S phase [4,21]. NIH 3T3 cells
expressing either vector or SphK1 were co-transfected with
CT-Acy1 or Acy1 and eﬀects on apoptosis induced by serum-
withdrawal determined by examining chromosomal conden-
sation and fragmentation. Interestingly, in contrast to their
inhibitory eﬀects on SphK1 activity, CT-Acy1 reduced while
Acy1 potentiated the anti-apoptotic eﬀect of SphK1 (Fig. 2B).
To address the possibility that interaction of Acy1 with
SphK1 regulates its mitogenic eﬀect, we also examined the
eﬀect of CT-Acy1 or Acy1 on proliferation. In agreement with
other studies [27–30], expression of SphK1 increased cell
growth as determined by MTT dye reduction assay. Once
again, CT-Acy1 had a diﬀerent eﬀect than full-length Acy1.
Whereas CT-Acy1 reduced the growth-promoting eﬀect of
SphK1, Acy1 enhanced it (Fig. 2C).
3.4. Acy1 induces redistribution of SphK1
SphK1 is a cytosolic enzyme, while its substrate sphin-
gosine is a lipid found in membranes. Therefore, it is likely
that SphK1 activity is regulated in part by its translocation
from the cytosol to membranes. Indeed, several previous
studies have shown that SphK1 translocates to membranes
upon activation [12,15,16,31]. It was therefore of interest to
determine whether Acy1 alters the localization of SphK1.First, we examined the localization of both proteins by
immunocytochemistry. In agreement with its cytoplasmic
expression [32], Acy1 had a diﬀuse cytosolic localization
when expressed in Cos7 cells (Fig. 3A and B). When SphK1
was expressed alone, it also showed a diﬀuse cytosolic ex-
pression pattern (Fig. 3C and D), with dispersed punctate
staining as reported previously [27]. However, when Acy1
and SphK1 were co-expressed, although both were still
predominantly cytosolic, there was also co-localization in
tubular structures (Fig. 3E–G, arrows) and at or near the
plasma membrane as indicated by the yellow color in the
merged pictures.
To further substantiate that expression of Acy1 induces
redistribution of SphK1 to the plasma membrane, we ex-
amined their localization by subcellular fractionation.
Transfected cells were lysed by freeze-thawing and centri-
fuged at 100 000 g. Pellets were then extracted with 1%
Triton X-100, generating a soluble fraction and a TI fraction
that contains cytoskeleton proteins, focal adhesions, and li-
pid rafts. As expected from the immunoﬂuorescence data,
when expressed alone, both proteins were predominantly
localized to the cytosolic fraction (Fig. 4). Interestingly,
when co-expressed with Acy1, a portion of SphK1 shifted
from the cytosol to the TS fraction (Fig. 4).4. Conclusions
Our results suggest that Acy1 is a bona ﬁde SphK1-inter-
acting protein that can inﬂuence not only its activity but also
its cellular localization. Acy1 also potentiated the mitogenic
and cytoprotective eﬀects of SphK1. Surprisingly, the CT-
Acy1, which also binds SphK1, reduced these eﬀects. Although
the physiological signiﬁcance of these observations is not yet
clear, our data suggest that CT-Acy1 may act as a dominant-
Fig. 3. Acy1 alters the intracellular distribution of SphK1. Cos7 cells were transfected with V5-Acy1 (A,B) or myc-SphK1 (C,D) or both (E–G) and
ﬁxed 48 h later. Cells were then incubated with anti-myc and anti-V5 antibodies and stained with Texas red anti-mouse IgG and FITC anti-rabbit
IgG. Phase (A,C) and ﬂuorescent (B,D,E–G) images were obtained with a Nikon TE-200 using a CoolSnap camera driven by MetaMorph software.
Panel G shows the superimposed merged pictures, yellow color represents co-localization of the two proteins. Arrows indicate long tubular structures
observed only when proteins were co-transfected.
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of CT-Acy1 blocks the ability of SphK1 to interact with en-
dogenous, active Acy1. This would block the pro-growth and
anti-apoptotic eﬀects of SphK1 if the aminoacylase activity of
Acy1 is required for its SphK1 regulatory eﬀects, because CT-
Acy1 is enzymatically inactive. It is also possible that the N-
terminus of Acy1, missing from CT-Acy1, may have binding
sites for other proteins required for the SphK1–Acy1 complexto inhibit apoptosis and promote cell growth or for its trans-
location to its site of action.
Because cellular levels of the bioactive sphingolipid mediator
S1P are low and tightly regulated, it is not surprising that cells
have evolved many mechanisms to control the activity of
SphK1, the critical enzyme responsible for formation of S1P,
as suggested by the discovery of a plethora of SphK1-inter-
acting proteins [17–20]. Most of them, including Acy1, have in
Fig. 4. Acy1 translocates SphK1 from the cytosol to the Triton-soluble
(TS) membrane fraction. HEK 293 cells were transfected with SphK1,
Acy1, or both. After 48 h, cells were harvested and lysed by freeze-
thawing. The lysates were centrifuged at 100 000 g to generate cy-
tosol (Cy) and pellet fractions. 1% Triton X-100 was added to the
pellet fractions and after centrifugation at 100 000 g, equal amounts
of the Triton X-100-insoluble (TI) and TS fractions were separated on
10% SDS–PAGE, transblotted to nitrocellulose, and probed with an-
tibodies to myc (SphK1) and V5 (Acy1) epitopes.
34 M. Maceyka et al. / FEBS Letters 568 (2004) 30–34common the ability to reduce SphK1 enzymatic activity and
aﬀect its cellular localization, directing it from a diﬀuse cyto-
plasmic expression to speciﬁc membranes where S1P produc-
tion can then be spatially and temporally regulated to inﬂuence
both intracellular and extracellular signaling pathways.
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